A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents
Jan Philipp Bewersdorf*, Rory M. Shallis, Elad Sharon, Silvia Park, Rahul Ramaswamy, Caroline E. Roe, Jonathan M. Irish, Anne Caldwell, Wei Wei, Abdulraheem Yacoub, Yazan F. Madanat, Joshua F. Zeidner, Jessica K. Altman, Olatoyosi Odenike, Swaroopa Yerrabothala, Tibor Kovacsovics, Nikolai A. Podoltsev, Stephanie Halene, Richard F. Little, Richard PiekarzSteven D. Gore, Tae Kon Kim*, Amer M. Zeidan*
Dive into the research topics of 'A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents'. Together they form a unique fingerprint.